Peptide · Fact sheet

Survodutide

Also known as BI 456906

Survodutide is not FDA approved. Phase 2 and Phase 3 trials have reported weight loss, reduced liver fat, and MASH-resolution signals, while fibrosis outcomes, longer-term benefits, safety, and regulatory decisions remain under study.

In clinical trialsModerate human evidence

What is Survodutide?

Survodutide is a manufactured peptide that activates both the glucagon and GLP-1 receptors.

The dual design aims to combine appetite and glucose effects with glucagon-related energy and liver biology, but mechanistic breadth can also create tradeoffs.

Benefits & claims

It is among the most advanced dual glucagon/GLP-1 candidates for obesity and metabolic liver disease.

Phase 3 liver-fat results strengthen the human evidence without turning an investigational program into an approved medicine.

What the evidence supports

  • A Phase 2 obesity trial reported substantial average weight reduction compared with placebo.
  • MASH and MASLD trials reported favorable resolution or liver-fat endpoints, while fibrosis and long-term clinical outcomes require further evidence.
Research areas
  • Obesity
  • Metabolic dysfunction-associated steatohepatitis
  • Liver fat and fibrosis
  • Type 2 diabetes
  • Chronic weight management
  • MASH and MASLD
  • Obesity with or without type 2 diabetes

Dosage & frequency

Human study context

Survodutide is an investigational GLP-1/glucagon agonist. Study escalation schedules do not establish an approved maintenance dose.

Phase 2 obesity dose-finding trial

Adults age 18–75 with BMI at least 27, without diabetes

Amount
Target groups 0.6, 2.4, 3.6 or 4.8 mg
Frequency
Once weekly for 46 weeks
Route studied or labeled
Subcutaneous

The study included twenty weeks of escalation; target amounts are not initial treatment amounts.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Evidence in obesity and MASH comes from distinct study populations and endpoints.

Interactions & precautions

  • Investigational dual-agonist trial safety does not establish compatibility with other incretin treatments or arbitrary combinations.

What is still unresolved

  • Final indication, regimen, tolerability, and long-term clinical outcomes remain unresolved.

Side effects & risks

  • Gastrointestinal adverse effects were the most frequent treatment-emergent problems in trials.
  • Discontinuation and incomplete exposure complicate estimates of real-world benefit.
  • Long-term glucagon-receptor effects and uncommon harms remain under study.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Moderate human evidence

Randomized Phase 2 studies and a Phase 3 MASLD study report meaningful weight and liver-fat effects. Those endpoints do not yet establish broad liver-outcome, cardiovascular, or long-term clinical benefit.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Little weight loss despite reduced hunger

A self-described blinded-trial participant reported slow weight loss, reduced hunger, headaches, constipation and nausea-like symptoms.

Amount, frequency, route and duration could not be confirmed for this account.

Treatment assignment was unknown. Diet and walking also changed, so neither symptoms nor weight change can be attributed to survodutide.

Read the original account
Mixed account · personal report

Less food preoccupation, with occasional diarrhea

Another trial commenter described early weight loss, less preoccupation with food, more energy and two diarrhea episodes.

Reported use in this account

Product
Blinded survodutide-study treatment; active drug or placebo not confirmed
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
About three weeks before the fourth reported dose

The author explicitly linked some improvements to changed diet and exercise and did not know whether they received placebo.

Read the original account

Approval status

Survodutide remains investigational in the United States and is being evaluated in Phase 3 obesity and metabolic liver-disease programs.

Late-stage obesity and liver-disease research

Survodutide has Phase 3 trial evidence and registry records, but it remains investigational until an FDA review supports approval for a defined use.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether liver-fat and MASH-resolution changes translate into fewer liver complications
  • Long-term cardiovascular, gallbladder, pancreatic, and metabolic outcomes
  • Durability of weight and liver effects
  • Whether the benefit-risk profile will support FDA approval

Summary

Survodutide remains investigational despite favorable metabolic and liver findings. Approval and longer-term clinical outcomes remain unresolved.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedRandomized Phase 2 obesity trial

    Controlled human study of body-weight efficacy, tolerability, and adverse events.

  2. pubmedRandomized Phase 2 MASH trial

    Biopsy-based MASH and fibrosis study with condition-specific endpoints.

  3. pubmedSYNCHRONIZE-MASLD Phase 3 trial

    Phase 3 liver-fat and body-weight trial with limited duration and geography.

  4. clinical trialsClinicalTrials.gov: SYNCHRONIZE-1

    Official Phase 3 obesity-study record and endpoint definitions.

How we assess sources · Suggest a correction